• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » TCT 2014: Another trial shows no benefit for renal denervation in hypertension

TCT 2014: Another trial shows no benefit for renal denervation in hypertension

September 17, 2014 By Brad Perriello

TCT 2014: Another Medtronic trial shows no benefit for renal denervation in hypertension

A small sham-controlled trial of Medtronic‘s (NYSE:MDT) Symplicity renal denervation device in treating mild but resistant hypertension failed to show any benefit for the therapy, echoing the results of the Symplicity-3 trial early this year.

The 71-patient Symplicity-Flex trial compared RDN with the sham procedure, using an endpoint of ambulatory blood pressure readings in patients with mild hypertension. After 6 months, the mean reduction from baseline was 7mmHg in the RDN arm and 3.5mmHg in the sham arm, not a statistically significant difference.

But excluding 2 patients with incomplete ablations, 1 who did not undergo the sham procedure and a 4th who did not meet the trials criteria because of renal artery stenosis, the study showed an 8.3mmHg reduction in the Symplicity-treated cohort and a 3.5mmHg reduction in the sham group, which was statistically significant.

Reporting the results at the annual Transcatheter Cardiovascular Therapies conference this week in Washington, Dr. Steffen Desch of the University of Leipzig Heart Center in Germany noted that the patient population in his Symplicity-Flex trial, which was not sponsored by Medtronic, was very different from the patients in the Symplicity-3 study, heartwire reported. The Symplicity-Flex study cohort showed a baseline systolic pressure of about 144mmHg, while the Symplicity-3 cohort’s baseline systolic was roughly 163mmHg, according to the website.

"This is a whole different patient population as compared with Symplicity HTN-3," said Desch, who noted that his clinic stopped performing RDN in January, just before Medtronic revealed the failed Symplicity-3 results.

Although he told MedPage Today that RDN for hypertension "may have an application in science, but not in the clinic except for the very rare patient," Desch said newer RDN devices with more electrodes might prove more effective than earlier devices, according to heartwire. Symplicity-Flex used 4 to 6 circumferential ablation runs of 2 minutes for each renal artery from distal to proximal, Desch said.

"If I were doing the trial again, I would recommend 10 to 12 ablations," he told the website.

"Given the fact that the magnitude of benefit in the per protocol analysis was small, it is certainly not conclusive evidence of a positive signal [for RDN in hypertension]," Dr. Deepak Bhatt of the Brigham and Women’s Hospital in Boston, who was a principal investigator in Symplicity-3, told MedPage Today.

Filed Under: News Well Tagged With: Clinical Trials, Hypertension, Renal, TCT 2014, Trade Show

More recent news

  • Real-world data backs Route 92 reperfusion system
  • LivsMed unveils new surgical robot with telesurgery capabilities
  • JenaValve enrolls first patient in TAVR for AR study
  • HistoSonics expands insurance coverage for histotripsy treatment
  • Johnson & Johnson MedTech gets updated FDA nod for Varipulse PFA

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy